ASTRAZENECA PHARMA Fact Sheet, ASTRAZENECA PHARMA Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA Fact Sheet    (AIDL)


EV Stocks: Which is Tanushree's Top Pick?


Here is the latest financial fact sheet of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA quarterly results and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

ASTRAZENECA PHARMA Price History

Price Rs 2,815.6
Mkt Cap Rs m 70,389
Vol '000 1.3
P/E X 99.8
P/CF X 62.1
EPS (TTM) Rs 28.2
1 Day % -0.3
No. of shares m 25.00
1 Week % -6.6
1 Month % -6.9
1 Year % -25.0
52 week H/L Rs 4,580.0/2,756.0
As on Jan 28, 2022 (Close)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ASTRAZENECA PHARMA Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
ASTRAZENECA PHARMA EQUITY SHARE DATA
High Rs1,2151,2782,1382,9404,970 
Low Rs9098839301,6352,348 
Sales per share (Unadj.) Rs215.5228.0291.3332.7325.4 
Earnings per share (Unadj.) Rs8.010.421.828.937.3 
Diluted earnings per shareRs8.010.421.828.937.3 
Cash flow per share (Unadj.) Rs14.416.327.736.345.4 
Dividends per share (Unadj.) Rs0001.002.00 
Adj. dividends per shareRs0.000.000.001.002.00 
Avg Dividend yield %00000.1 
Book value per share (Unadj.) Rs88.597.9119.5145.1181.8 
Adj. book value per shareRs88.597.9119.5145.1181.8 
Shares outstanding (eoy) m25.0025.0025.0025.0025.00 
Bonus / Rights / Conversions  ----- 
Price / Sales ratio x4.94.75.36.911.2 
Avg P/E ratio x132.4104.270.479.298.0 
P/CF ratio (eoy) x74.066.455.363.080.6 
Price / Book Value ratio x12.011.012.815.820.1 
Dividend payout %0003.55.4 
Avg Mkt Cap Rs m26,55027,00738,34457,19791,478 
No. of employees `000NANANANANA 
Total wages/salary Rs m1,6201,5041,9742,1672,195 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
ASTRAZENECA PHARMA INCOME DATA
Net Sales Rs m5,3885,7007,2838,3188,136 
Other income Rs m144123163130128 
Total revenues Rs m5,5325,8237,4468,4488,264 
Gross profit Rs m3694637131,2071,355 
Depreciation Rs m158147149186201 
Interest Rs m0001111 
Profit before tax Rs m3554387271,1401,271 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m155179182418338 
Profit after tax Rs m201259545722933 
Gross profit margin %6.98.19.814.516.7 
Effective tax rate %43.540.825.136.626.6 
Net profit margin %3.74.57.58.711.5 
ASTRAZENECA PHARMA BALANCE SHEET DATA
Current assets Rs m2,6333,3264,1335,8226,887 
Current liabilities Rs m2,0212,1872,6763,6713,734 
Net working cap to sales %11.420.020.025.938.8 
Current ratio x1.31.51.51.61.8 
Inventory Days Days108105484345 
Debtors Days Days2935403738 
Net fixed assets Rs m2,5032,4271,7781,9351,855 
Share capital Rs m5050505050 
"Free" reserves Rs m2,1622,3992,9373,5794,496 
Net worth Rs m2,2122,4492,9873,6294,546 
Long term debt Rs m00000 
Total assets Rs m5,1365,7535,9127,7578,742 
Interest coverage xNMNMNM101.0117.6 
Debt to equity ratio x00000 
Sales to assets ratio x1.01.01.21.10.9 
Return on assets %3.94.59.29.510.8 
Return on equity %9.110.618.219.920.5 
Return on capital %16.017.924.331.728.2 
Exports to sales %00000 
Imports to sales %23.435.327.037.029.3 
Exports (fob) Rs m00000 
Imports (cif) Rs m1,2612,0151,9633,0802,382 
Fx inflow Rs m216300236305318 
Fx outflow Rs m1,3202,0151,9633,0802,382 
Net fx Rs m-1,103-1,715-1,727-2,775-2,064 
ASTRAZENECA PHARMA CASH FLOW
From Operations Rs m 381 88 550 874 1,048 
From Investments Rs m 3 -94 43 -1,708 1,730 
From Financial Activity Rs m 0 0 0 -64 -90 
Net Cashflow Rs m 384 -6 593 -897 2,688 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 75.0%
Institution 3.5%
Non-Institution 21.5%
Total 100.0%
Free Float 25.0%
Pledged promoter holdings 0.0%
Shareholding as on Dec 2021
 

Company Information

Regd Off Block N1 12th Floor, Manyata Embassy Business Park, Rachenahalli Outer Ring Road, Bengaluru - 560045
E-mail comp.secy@astrazeneca.com Web www.astrazenecaindia.com/india
Tel 080 6774 8000 Fax 080 6774 8557
Sector PHARMACEUTICALS Group Astrazeneca Pharma India - MNC
Tr Agent Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd), 30 Ramana Residency, 4th Cross Sampige Road, Malleswaram
Auditor BSR & Co.
CHM: D. E. Udwadia COMP SEC: Anantha Murthy YEAR OF INC: 1979 BSE CODE: 506820 FV (Rs): 2 DIV YIELD (%): 0.1

Read: ASTRAZENECA PHARMA 2020-21 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    

Compare ASTRAZENECA PHARMA With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    




Today's Market

Indian Indices End Flat Amid High Volatility; Maruti Suzuki & Tech Mahindra Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Views on news

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 45.0% (Quarterly Result Update)

Aug 11, 2021 | Updated on Aug 11, 2021

For the quarter ended June 2021, ASTRAZENECA PHARMA has posted a net profit of Rs 102 m (down 45.0% YoY). Sales on the other hand came in at Rs 2 bn (down 9.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY21); Net Profit Up 184.8% (Quarterly Result Update)

Jul 8, 2021 | Updated on Jul 8, 2021

For the quarter ended March 2021, ASTRAZENECA PHARMA has posted a net profit of Rs 273 m (up 184.8% YoY). Sales on the other hand came in at Rs 2 bn (up 7.9% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look? (Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

5 Hidden Tata Group Companies to Add to Your Watchlist (Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

Insiders are Buying into these 6 Stocks Aggressively. More Details here... (Views On News)

Jan 19, 2022

While promoter holding is an important parameter, it should not be the sole reason for buying a stock.

Top Indian Drone Companies to Watch Out for in 2022 (Views On News)

Jan 21, 2022

Several companies are adopting drone technology for regular business operations.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS